Literature DB >> 14660670

Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.

Carol Heath1, Nicholas C P Cross.   

Abstract

The 8p11 myeloproliferative syndrome is an aggressive disorder caused by FGFR1 fusion proteins resulting from a subset of acquired translocations that target chromosome band 8p11. These chimeric proteins have constitutive FGFR1 tyrosine kinase activity and are believed to deregulate hemopoietic development in a manner analogous to BCR-ABL in chronic myeloid leukemia. Here we have studied the role of STAT proteins in transformation mediated by the most common of these fusions, ZNF198-FGFR1. We found that STATs 1, 3, and 5 were activated constitutively in ZNF198-FGFR1-transformed Ba/F3 cells and that STATs 2, 4, and 6 were also tyrosine-phosphorylated. Induction of dominant negative STAT mutants showed that activation of STAT5, but not STATs 1 or 3, was essential for the anti-apoptotic effect of ZNF198-FGFR1 and that STAT5 activation is essential for the elevated levels of BclXL in transformed cells. STAT5 activation was also shown to be required for continued cell cycle progression of BaF3/ZNF198-FGFR1 cells in conditions of cytokine deprivation and for up-regulation of the DNA repair protein Rad51. These findings suggest a critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660670     DOI: 10.1074/jbc.M308743200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Growth factor receptors as regulators of hematopoiesis.

Authors:  Michael A Weinreich; Ingrid Lintmaer; Linlin Wang; H Denny Liggitt; Michael A Harkey; C Anthony Blau
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

2.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

3.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

4.  Analysis of transcriptional modulation of the presenilin 1 gene promoter by ZNF237, a candidate binding partner of the Ets transcription factor ERM.

Authors:  Martine Pastorcic; Hriday K Das
Journal:  Brain Res       Date:  2006-11-28       Impact factor: 3.252

5.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

6.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Authors:  Chitta Kasyapa; Ting-Lei Gu; Lalitha Nagarajan; Lalitha Natarajan; Roberto Polakiewicz; John K Cowell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

Review 7.  STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells.

Authors:  Hein Schepers; Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  JAKSTAT       Date:  2012-01-01

Review 8.  Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Authors:  Sandrine Medves; Jean-Baptiste Demoulin
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

Review 9.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

10.  The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation.

Authors:  Shiyuan Hong; Laimonis A Laimins
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.